We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




AI-Powered Platform Enables Rapid Point-of-Care Cancer Testing

By LabMedica International staff writers
Posted on 19 May 2025

One of the major hurdles in oncology is performing advanced genomic testing quickly enough to provide oncologists with actionable results that can lead to the best possible patient outcomes. More...

A new intelligent cancer solution aims to address this challenge by enabling labs and oncologists globally to accelerate targeted treatments, ultimately reducing costs while enhancing patient-focused care.

Avitia (Montreal, Canada) has introduced an artificial intelligence (AI)-powered rapid cancer testing platform that grants laboratories and clinicians access to advanced molecular testing directly on-site, regardless of their location. This innovation enables healthcare teams to quickly gather cancer insights and initiate treatment at a faster pace, all while offering a more cost-effective alternative to existing send-out testing methods. Research has shown that long travel distances remain a significant barrier to accessing high-quality cancer care, which directly impacts patient outcomes. Avitia’s modular technology enables cancer centers to perform NGS tests on-site, cutting down turnaround times and reducing expenses compared to centralized labs that rely on send-out services.

With AI-driven bioinformatics designed to meet regional and patient-specific needs, Avitia helps oncologists overcome logistical challenges and test patients more efficiently. These data-driven insights ensure that every patient receives care that is both precise and personalized. Utilizing minimally invasive liquid biopsy technology, Avitia’s platform has shown promise in improving patient monitoring and treatment responses, particularly for aggressive endometrial and ovarian cancers. A recent retrospective study highlighted that Avitia’s liquid biopsy technology enabled researchers to detect disease recurrence months before conventional clinical, radiologic, and biomarker progression methods. Currently, Avitia’s technology is being used by partners in Canada, the United States, and Southeast Asia, with over 40,000 life-saving cancer mutation tests already conducted using this platform.

“Avitia believes that all patients deserve access to advanced, cost-effective testing, regardless of geographic or economic constraints,” said Avitia CEO James Lumsdaine.

Related Links:
Avitia


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Serological Pipet Controller
PIPETBOY GENIUS
New
Automated Microscope
dIFine
New
Silver Member
Quality Control Material
Multichem ID-B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: Micrograph showing the distribution of misfolded proteins in myeloma cells (Photo courtesy of Helmholtz Munich)

Novel Method Tracks Cancer Treatment in Cells Without Dyes or Labels

Multiple myeloma is a blood cancer that affects plasma cells in the bone marrow, leading to abnormal protein production, weakened immunity, and organ damage. Traditional methods for evaluating myeloma... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.